Acceleron (XLRN) option implied volatility flat into Phase III Believe results

Acceleron Pharma (NASDAQ: XLRN) July call option implied volatility is at 62, August is at 56; compared to its 52-week range of 37 to 152 into announcing with its partner Celgene (CELG) positive Phase III Believe results for luspatercept in transfusion dependent beta thalassemia.

You May Also Be Interested In

• Mosaic (MOS), Others Lower Following Trump Post on Potash from Belarus
• LendingTree (TREE) 2877 contracts of October 30 calls trade, share price up 4.6%
• AutoZone (AZO) call put ratio 1 call to 1.4 puts into quarter results